Pharmaceuticals, Healthcare, and Research by Bristol Myers Squibb

  • Oleg Tkachenko
  • 2 hours ago
Bristol-Myers Squibb Company shares positive 56-week trial results: Can BMY recover above the MA-50?
Bristol-Myers Squibb shared new positive 56-week data from its Phase 3 trial in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. The stock is down 1.5% on the day at ...
  • Mykhailo Ihnatenko
  • 26.10.2026
Bristol-Myers Squibb announces Phase 3 trial results after stock ends session down 2.4%
Bristol-Myers Squibb announced results from a late-stage trial of its investigational therapy for certain EGFR-mutant non-squamous non-small cell lung cancer patients at ESMO26. The stock is down ...
  • Anton Kharitonov
  • 08.09.2026
Bristol-Myers Squibb announces positive Phase 2 results: Will BMY hold the MA-20?
Bristol-Myers Squibb announced positive topline results from a Phase 2 trial of an investigational CAR T cell therapy for certain patients with relapsed or refractory multiple myeloma. The stock ...
  • Andreas Kristo
  • 10.08.2026
$2.3B Houston manufacturing campus investment lifts Bristol-Myers Squibb stock
Bristol-Myers Squibb announced a $2.3 billion plan to build a new manufacturing campus in Houston, Texas. Shares edge higher on the day, trading at $64.72.Bristol-Myers Squibb announced a $2.3 ...
  • Ashutosh Sureka
  • 17.06.2026
Bristol-Myers Squibb stock trades lower with weekly decline intensifying amid bearish momentum
Bristol-Myers Squibb opened its NYNJ World Cup 26 Jersey Fan Hub, featuring mascot Squibby, in New Jersey.The company stated that it is standing shoulder to shoulder with communities to advance ...
  • Parshwa Turakhiya
  • 10.06.2026
Bristol-Myers Squibb stock closes near weekly low amid persistent short-term pressure
Bristol-Myers Squibb said its commitment to patient outcomes continues as the world prepares for the 2026 FIFA World Cup.The company promoted its #BMSWontLose campaign in a recent tweet. ...